Li Auto (LI) Q1 2025 Earnings Call May 29, 2025 08:00 AM ET Company Participants Janet Zhang - Director of Investor RelationsTie Li - CFO & Executive DirectorYan Xie - Chief Technology OfficerBin Wang - VP - Investment BankingPaul Gong - Executive Director Conference Call Participants Tim Hsiao - AnalystYingbo Xu - AnalystTina Hou - AnalystJing Chang - Analyst Operator Ladies and gentlemen, thank you for standing by for Lee Auto's First Quarter twenty twenty five Earnings Conference Call. At this time, all ...

Li Auto (LI) Q1 2025 Earnings Call May 29, 2025 08:00 AM ET Speaker0 Ladies and gentlemen, thank you for standing by for Lee Auto's First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in listen only mode. Today's conference call is being recorded. I will now turn the call over to your host, Ms. Janet Zhang, Investor Relations Director of Li Auto. Please go ahead, Janet. Speaker1 Thank you, Kelly. Good evening, and good morning, everyone. Welcome to Li Auto's first q ...

Company Overview - Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment [3] - The company aims to leverage the adaptive immune system's capabilities, which are considered nature's most finely tuned diagnostic and therapeutic tools for various diseases [3] - Adaptive Biotechnologies operates two business segments: Minimal Residual Disease (MRD) and Immune Medicine, developing products for cancer and autoimmune disorders [3] Upcoming Events - The company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL [1] - Management is scheduled for a fireside chat on June 11 at 5:40 a.m. Pacific Time / 8:40 a.m. Eastern Time, with a live and archived webcast available on the company website [2]

2025 年展望：2025 年 5 月，黑芝麻宣布其 A1000 SoC 搭载于东风新款车型（链接）—— 东风风神 007 的 2025 款。凭借 A1000 SoC 的 58 TOPS 计算能力，东风风神 007 配备了 20 多项智能驾驶辅助功能、 高速公路导航和 LAPA（远程自动泊车辅助）。随着中国 AD/ADAS 趋势的发展以及与中国主要 OEM 的密切合作，管理层旨在进入更多主要 OEM 的供应链，并在 2025 年实现两位数的收入增长。 竞争动态：管理层对其在汽车芯片组方面的实力保持乐观，并认为汽车 OEM 自行开发芯片组并非易 事，因为开发芯片组设计、神经网络处理单元（NPU）和工具包需要时间，而且单个汽车 OEM 的销量 较小，可能难以覆盖开发成本。在软件方面，公司继续与合作伙伴开发算法，如旷视科技、 Deeproute.ai、大疆等。通过第三方软件供应商，公司还可以更好地了解软件市场，客户可以更灵活地 选择软件 / 算法。 关键要点 黑芝麻（2533.HK）是一家 AD/ADAS 系统级芯片（SoC）供应商，为汽车 OEM 客户提供多种产品， 包括 A1000/A1000L/A1000 P ...

General Motors is investing $888 million in its Tonawanda Propulsion plant in Buffalo, New York, "to support the production of the sixth generation of GM's V-8 engines," the automaker announced Tuesday. The investment is a shift from a previously announced $300 million commitment to make electric-vehicle drive units at the plant, as the V-8 engines are used in GM's full-sized trucks and SUVs. GM says the newer engines will provide drivers better fuel economy and reduce emissions by utilizing "new combustion ...

Core Insights - Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines aimed at improving treatment options for cancer and inflammatory diseases [3] - The company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, featuring its president and CEO, Arthur T. Sands, M.D., Ph.D., and CFO, Hans van Houte [1] Company Overview - Nurix's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with a focus on enhancing immune cell activation [3] - The company is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline [3] - Nurix has partnered with Gilead Sciences, Sanofi, and Pfizer, retaining options for co-development, co-commercialization, and profit sharing in the U.S. for several drug candidates [3] - The company utilizes a fully AI-integrated discovery engine and has significant expertise in ligase, providing a competitive advantage in translating targeted protein degradation into clinical advancements [3]

HOUSTON, TX, May 23, 2025 (GLOBE NEWSWIRE) -- Key Points: Extreme Animals Alive opens May 24 at HMNS (members see it first May 23), and invites guests to investigate the stunning variety of animal adaptations found in the natural world.Animals within the exhibit include vinegaroons, Savannah monitors, axolotls, fennec foxes, and many more.Visitors learn about animal adaptations, including those that allow animals to shape-shift, glow, endure extreme temperatures, or even control the minds of other animals. ...

Summary of Nurix Therapeutics (NRIX) 2025 Conference Call Company Overview - Nurix Therapeutics specializes in targeted protein degradation, utilizing small molecules to degrade proteins via the ubiquitin proteasome system, rather than inhibiting them [3][4] - The company has developed a robust research platform called Dell AI, which includes large DNA encoded libraries for screening various protein targets [3] Key Programs and Developments - **Bexabrutinib**: - A BTK degrader moving into Phase II and Phase III studies in the second half of the year [4] - Target indications include Chronic Lymphocytic Leukemia (CLL) and Waldenstrom's macroglobulinemia [6] - Reported an 80% overall response rate (ORR) in heavily pretreated CLL patients [8] - Safety profile appears favorable with no new safety signals reported [10] - **Clinical Trials**: - Plans to initiate pivotal studies this year, focusing on a single-arm, single-agent accelerated approval strategy in third-line settings [15] - A randomized controlled study will also be initiated in the second-line plus setting [16] - Updates on trial designs and control arms expected mid-year [20] Competitive Landscape - BTK degradation is gaining enthusiasm in the investigator community as a new treatment modality, particularly for patients who have failed previous BTK inhibitors [12] - Nurix aims to differentiate its BTK degrader by addressing clinically relevant resistance mutations that arise from chronic treatment with BTK inhibitors [12] Strategic Partnerships - Collaborations with Gilead, Sanofi, and Pfizer are progressing well, with Gilead's IRAK4 program moving into clinical studies [30] - Sanofi is expected to advance the STAT6 development candidate towards IND status within approximately 12 months [30] Pipeline Expansion - Nurix is exploring indications beyond oncology, particularly in autoimmune diseases, with plans to initiate studies in autoimmune hemolytic anemia [27] - The company is cautious about funding these additional programs due to capital market challenges [28] Additional Assets - **NX-2127**: An oral BTK degrader showing promising results in aggressive malignancies, with rapid and long-lasting complete responses reported [38] - **Preclinical Programs**: Nurix is open to additional collaborations and has a pan-mutant BRAF degrader that addresses various mutations and resistance mechanisms [45] Financial Position - Nurix maintains a strong cash position and runway to advance its programs, with revenue contributions from collaborations helping to offset expenses [4] Conclusion - Nurix Therapeutics is at a pivotal point in its development, transitioning from a Phase I to a Phase II/III company with promising data and strategic partnerships that enhance its pipeline and market position [4][24]

RTX Corporation’s (RTX) business segment, Raytheon, recently shipped the first AN/TPY-2 radar, outfitted with full Gallium Nitride (GaN) technology, to the U.S. Missile Defense Agency. The radar is also configured with the next-generation CX6 high-performance computing software, which enables more precise target discrimination and electronic attack protection.Such deliveries should bolster RTX’s revenue performance from radars and get duly reflected in its second-quarter 2025 results.RTX's Expertise in Crea ...

Arbe Robotics (ARBE) Q1 2025 Earnings Call May 20, 2025 08:30 AM ET Company Participants Miri Segal-Scharia - Investor RelationsKobi Marenko - CEO, Co-Founder & DirectorKarine Pinto-Flomenboim - Chief Financial Officer Conference Call Participants George Gianarikas - Managing Director and Senior AnalystSuji Desilva - Managing Director, Senior Research AnalystMatthew Galinko - SVP & Senior Research Analyst Operator Good day, and welcome to the Arbe Robotics First Quarter twenty twenty five Earnings Results C ...